U.K. Ophthalmology Spin-Out Raises £8m For DME Programs
SV Life Sciences and Novo AS support spin-out KalVista with £8m to advance preclinical DME programs.
SV Life Sciences and Novo AS support spin-out KalVista with £8m to advance preclinical DME programs.